California First Leasing Corp Takes Position in Halozyme Therapeutics, Inc. $HALO

California First Leasing Corp purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the first quarter, Holdings Channel.com reports. The fund purchased 30,300 shares of the biopharmaceutical company’s stock, valued at approximately $1,958,000.

Other large investors have also bought and sold shares of the company. Clark Capital Management Group Inc. increased its holdings in Halozyme Therapeutics by 14.4% in the 3rd quarter. Clark Capital Management Group Inc. now owns 202,965 shares of the biopharmaceutical company’s stock worth $14,885,000 after acquiring an additional 25,582 shares during the last quarter. Allworth Financial LP lifted its holdings in Halozyme Therapeutics by 322.5% during the third quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock valued at $2,914,000 after purchasing an additional 30,331 shares during the last quarter. Element Squared LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at about $1,193,000. Dimensional Fund Advisors LP boosted its position in Halozyme Therapeutics by 3.2% during the third quarter. Dimensional Fund Advisors LP now owns 2,078,426 shares of the biopharmaceutical company’s stock worth $152,431,000 after purchasing an additional 63,699 shares during the period. Finally, CWA Asset Management Group LLC bought a new position in Halozyme Therapeutics during the fourth quarter worth about $907,000. 97.79% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the sale, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the sale, the director directly owned 42,044 shares of the company’s stock, valued at $3,225,195.24. This represents a 3.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 72,179 shares of company stock valued at $5,052,400 in the last three months. Company insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on HALO shares. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, June 16th. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. UBS Group reissued a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Finally, Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Price Performance

HALO stock opened at $79.45 on Monday. The stock has a 50-day simple moving average of $69.41 and a two-hundred day simple moving average of $69.46. Halozyme Therapeutics, Inc. has a twelve month low of $53.33 and a twelve month high of $82.22. The firm has a market capitalization of $9.42 billion, a PE ratio of 28.58, a PEG ratio of 0.33 and a beta of 0.84. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. During the same period in the prior year, the firm posted $1.11 earnings per share. The company’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.